Track market-moving stories before they get noisy

What happenedAccording to its SEC filing dated May 15, 2026, Frontier Capital Management increased its position in Stride (LRN +1.20%) by 1,388,589 shares during the first quarter. The estimated trade value was $112.63 million, calculated using the quarter’s average closing share price. At quarter end, the Stride stake was valued at $136.60 million, an increase of $126.17 million from the prior period.

What else to knowFrontier Capital Management bought more Stride, bringing its stake to 1.4% of 13F AUM.

Top holdings after the filing:FTAI Aviation: $260.24 million (2.7% of AUM)Darling Ingredients: $151.88 million (1.6% of AUM)United Therapeutics: $149.85 million (1.5% of AUM)Circle Internet Group: $147.71 million (1.5% of AUM)Granite Construction: $142.39 million (1.5% of AUM)As of May 20, 2026, Stride shares were trading at $89.06, down 45.1% over the past year and underperforming the S&P 500 by 70 percentage points.

Company overviewMetricValuePrice (as of market close May 20, 2026)$89.06Market capitalization$3.79 billionRevenue (TTM)$2.54 billionNet income (TTM)$308.12 millionCompany snapshotStride delivers technology-based educational services and online curriculum for K-12 students, as well as career learning programs for adult learners through brands such as Galvanize, Tech Elevator, and MedCerts.The company generates revenue by providing integrated educational platforms, digital courses, and professional development services to public and private schools, school districts, and individual consumers.Primary customers include public and private educational institutions, charter boards, individual learners, employers, and government agencies in the United States and internationally.Stride is a leading provider of online and blended education solutions, serving over 7,800 employees and a diverse client base in the education and workforce development sectors. The company leverages proprietary technology and specialized content to deliver scalable, individualized learning experiences across K-12 and adult education markets. Its strategic focus on both core academic and career-oriented programs positions Stride as a differentiated player in the evolving education services industry.

What this transaction means for investorsFrontier Capital Management likes to look for smaller stocks with “relative” value, and its Q1 purchase of Stride certainly fits this strategy. The firm began buying LRN stock in Q3 2024, but the position never exceeded 0.2% of Frontier’s portfolio. Q1’s purchase marks a huge departure from its small sizing after the company added $113 million in Stride stock, making it a 1.4% position -- the firm’s sixth-largest holding.

I think this hefty purchase makes a lot of sense, and I did something similar, buying the stock after it crashed by 50% when management announced that a platform upgrade went wrong and caused the company to miss out on thousands of new registrations. As bad as this was at the time, it seems like Stride has resolved the tech issues, and its registrations have somewhat normalized. Most importantly, management reiterated that it plans to grow sales by 10% annually and to reach $8 in EPS by 2028 -- which would make today’s share price around $89 rather reasonable.

While Stride will have to face the increasingly loud hum of being “disrupted” by AI, I think educational regulations and the need for a “human-in-the-loop” in the learning process give the company a moat. As more parents search for alternatives outside of traditional on-location public schools -- and perhaps seek adult learning classes of their own through Stride -- the company remains one of my favorite consumer staples stocks to buy at a discount today.

Josh Kohn-Lindquist has positions in Circle Internet Group and Stride. The Motley Fool has positions in and recommends Stride and United Therapeutics. The Motley Fool recommends Darling Ingredients and recommends the following options: short July 2026 $55 calls on Darling Ingredients. The Motley Fool has a disclosure policy.

Voss Capital disclosed a significant purchase of Stride (LRN +1.20%) in its May 15, 2026, SEC filing, adding 711,726 shares in a transaction estimated at $57.73 million based on quarterly average pricing.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Voss Capital increased its position in Stride (LRN +1.20%) by 711,726 shares during the first quarter. The estimated value of the shares acquired is $57.73 million, based on the average closing price over the quarter. The fund’s total position value in Stride rose by $65.97 million, a figure that includes both trading activity and stock price changes.

What else to knowThis was a buy; the Stride stake represented 3.98% of Voss Capital’s reportable 13F assets under management as of March 31, 2026.Top holdings after the filing:NASDAQ: FLYW: $158.59 million (9.1% of AUM)NASDAQ: CLBT: $133.32 million (7.6% of AUM)NYSE: GFF: $132.64 million (7.6% of AUM)NYSE: SRE: $121.95 million (7.0% of AUM)NASDAQ: EEFT: $104.53 million (6.0% of AUM)As of May 14, 2026, Stride shares were priced at $88.40, down about 40% from one year earlier and trailing the S&P 500, which is instead up about 28%.Company overviewMetricValuePrice (as of market close May 14, 2026)$88.40Market capitalization$4 billionRevenue (TTM)$2.54 billionNet income (TTM)$308.12 millionCompany snapshotStride delivers online curriculum, proprietary software systems, and educational services for K-12 students, as well as career learning programs for adult learners in fields such as information technology, healthcare, and business.The company generates revenue through a combination of integrated educational packages for virtual and blended public schools, individual online courses, supplemental learning products, and career training services marketed under brands like Galvanize, Tech Elevator, and MedCerts.Primary customers include public and private schools, school districts, charter boards, individual consumers, employers, and government agencies, both in the United States and internationally.Stride is a leading provider of technology-driven education solutions. The company leverages proprietary platforms and a broad portfolio of educational offerings to address the needs of K-12 students and adult learners seeking career advancement. Its scale and integration of curriculum, technology, and support services position it as a key player in the evolving education and training sector.

What this transaction means for investorsDespite Stride stock being down sharply from last year, Voss Capital appears to be focusing on what the business is doing, which is a good reminder of what long-term investors should be focused on. According to the firm’s latest results, Stride’s revenue from Career Learning rose 12.3% in the third fiscal quarter, while middle and high school Career Learning revenue jumped nearly 16% (helping to offset weakness in the adult segment). Enrollment in those programs increased 11.6%, reinforcing management's thesis that students increasingly want education tied directly to workforce outcomes.

Meanwhile, overall revenue increased 2.7% to $629.9 million during the quarter, while adjusted EBITDA climbed to $171.3 million. Over the first nine months of fiscal 2026, revenue rose 7.4% to $1.88 billion, and adjusted EBITDA increased 13.4% to $467.8 million. The company also narrowed its full-year outlook and ended March with $856 million in cash, cash equivalents, and marketable securities.

While quarterly earnings dipped modestly from last year, the broader trend remains encouraging. Stride is investing heavily in curriculum, software, and career-focused programs while still producing substantial profitability. And if that continues, then the stock could be due for a turnaround.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cellebrite, Euronet Worldwide, and Stride. The Motley Fool has a disclosure policy.

Carmax NYSE: KMX shares are trading near five-year lows, offering an intriguing opportunity. However, as insulated as it is from financial implosion, market forces are aligned to keep this stock from rising.

CarMax Today

$50.99 -0.58 (-1.12%)

As of 12:11 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$30.26▼

$71.99P/E Ratio31.81

Price Target$41.73

Get CarMax alerts:

The takeaway from the fiscal Q4 20256 results and foward guidance is that business conditions are less than optimal, so bad, in fact, that management paused its share buybacks in order to preserve capital. This is a very significant detail, as the fiscal year 2025 (FY2025) buyback activity reduced the count by a high single-digit amount.

The likely outcome is that Carmax weathers the changes well and comes out ahead. The question is how long it may take and how low the stock price may go before it does.

Carmax Near Price Floor: Sell-Side Support Isn’t FirmTechnically speaking, this stock is trading near a potential price floor in early Q2 2026, aligned with COVID-19 era lows. The problem is that the 2020 activity led to a quick turnaround, while price action in 2026 languishes at low levels with nothing to invigorate buyers. Analysts, who might put a floor in the action, are unlikely to, given the guidance update and sentiment trend.

The data tracked by MarketBeat reveals a high conviction Reduce rating, based on 18 analysts, and sentiment has been deteriorating. The 2026 trend includes numerous downgrades and price target reductions, with consensus assuming fair value near the technical floor and the low end at $28. In this scenario, KMX stock can easily fall to fresh lows and then shed more than 25% before hitting bottom.

And short sellers are selling into this market. The short interest isn’t astronomically high at 10%, but it has been increasing in recent reports and would be sufficient to provide a headwind for price action. Additionally, short interest may increase, given the pause in buybacks and potential weakness in upcoming reports. The deciding factor will be the institutions. They own a significant 99% of the market, and their activity is ambiguous.

The data reflects institutional accumulation in early 2026, ahead of the Q1 release, but the trailing 12-month balance is even. Selling and buying are balanced, reflecting a market in limbo and highly susceptible to news. The risk is that the 2026 guidance and buyback activity lead them into outright distribution and send the stock price through its critical support target to fresh lows. Short-sellers are likely to lean into their trade in that scenario, adding momentum and depth to any price decline that comes.

Carmax Headwinds Build, Impair Outlook for 2026Carmax struggled in its fiscal Q4, with margins declining amid weak demand and pricing actions. The company’s total unit sales increased by 0.7%, led by a 3% advance in Wholesale and offset by an 0.8% decline in retail. Comp units fell by nearly 2%. Total retail sales fell by more than 1%, and guidance didn’t leave the market feeling optimistic.

Margin news was also poor. The adjusted earnings per share came in above MarketBeat’s reported consensus, despite being affected by one-offs and overshadowed by weak margin guidance. The critical details are that the adjusted 34 cents in earnings was down more than 40% year over year, including the positive impact of share buybacks. Margin contraction is expected to continue.

Rising Debt and Margin Impairment Sap Enthusiasm for KMX StockOther bad news includes the balance sheet and debt levels. The company isn’t on the verge of bankruptcy, but 2025 activities resulted in reduced cash, increased inventory, and less equity, with leverage above target and weakness expected in the year ahead. Guidance forecasts additional cost savings from turnaround efforts, but these are offset by reduced margins and overall profitability.

Risks include a shrinking margin and the impact of intense competition. Carmax is behind the curve on its digital offerings and is struggling to gain share against operators such as Carvana. Its end-to-end digital process resonates with consumers, enabling quick, easy access to hassle-free automobile shopping. Carmax has similar features but achieves only a low double-digit percentage of 100% digital sales. Carvana NYSE: CVNA, on the other hand, sells more of its vehicles digitally and realizes higher margins as a result.

Catalysts this year will include operational improvements linked to the new CEO. Keith Barr took over earlier this year and is expected to drive operational improvements alongside digitization. Market share gains are also possible, as smaller used-car dealers are forced to consolidate. The question is whether Carmax can capitalize on the opportunity ahead of its competitors and do it profitably. Interest rate trends may also improve, increasing consumer appetite for pre-owned cars. As it is, the market is pricing in a slow pace of rate reduction, with the next cut not priced into futures trading until sometime in 2027.

Should You Invest $1,000 in CarMax Right Now?Before you consider CarMax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CarMax wasn't on the list.

While CarMax currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Shares of CarMax (KMX 1.22%) took a significant hit recently, dropping sharply following the company's latest quarterly earnings report. The decline added to an already tough backdrop for the stock. Shares are now down 37% over the last 12 months and 69% over the past five years.

With the stock price taking a beating, investors may be wondering if the used-car retailer is finally trading at a bargain. After all, beneath the headline losses, the company did see sequential improvements in its sales volume.

But a closer look at the company's financial health, management's decision to pause share repurchases, and the stock's valuation suggests investors may want to exercise some caution.

Image source: Getty Images.

A transition period For its fiscal fourth quarter of 2026 (the period ended Feb. 28, 2026), CarMax reported net sales and operating revenues of roughly $5.95 billion. This represented a 1% decline from the year-ago period.

While a decline isn't exactly what investors want to see, it actually marked a meaningful improvement from the fiscal third quarter, when revenue fell 7% year over year.

The underlying unit volume tells a similar story. Retail used unit sales slipped 0.8% year over year in fiscal Q4 -- a significant improvement compared to the 8% decline the company saw in fiscal Q3.

Management pointed out that it achieved this improvement in sales trends by lowering prices and increasing its marketing spend.

"We felt like, lower the prices, get sales moving in the right direction, and then pay for it by taking cost out of the business," explained interim executive chair Tom Folliard during the company's fiscal fourth-quarter earnings call.

When asked about the exact drivers of the improved volume, CarMax chief financial officer Enrique Mayor-Mora added: "I would tell you, out of those three things, pricing certainly we believe had the biggest impact, although we think all of those levers impacted our trend positively."

But these price cuts seem to have come at a cost to the company's profitability.

CarMax's gross profit margin contracted, with its total gross profit falling 9% year over year to $605 million during the quarter. And the bottom line was even uglier. The company reported a net loss of $121 million, or $0.85 per share -- though this was heavily weighed down by a $141 million non-cash goodwill impairment charge and restructuring costs. When excluding these items, adjusted earnings per share came in at $0.34 -- a sharp decline from the $0.64 it reported in the same quarter last year.

A paused buyback program In addition to margin pressure, another issue could be keeping investors on the sidelines: CarMax paused its share repurchases.

During the fourth quarter, the company repurchased only about $50 million of its stock before halting the program (it repurchased $632 million for the full fiscal year).

Mayor-Mora noted that the decision was made because the company's leverage is currently "slightly above the targeted range."

For a company that has historically used share buybacks to return capital to shareholders and support earnings-per-share growth, this pause is notable.

And this cautious capital allocation approach comes during a broader leadership transition, as newly appointed chief executive officer Keith Barr, who took the helm in March, is leading efforts to improve execution and drive efficiencies.

Today's Change

(

-1.22

%) $

-0.63

Current Price

$

50.94

Time to buy? With the business clearly in a transition period, what should investors make of the stock's valuation?

Even after the recent sell-off, CarMax stock arguably isn't cheap enough to make it a compelling buy. Based on its trailing 12-month adjusted earnings, shares trade at a price-to-earnings ratio of about 14.

While that multiple may not seem overly expensive on the surface, it leaves very little room for error, given the company's soft sales, contracting margins, and elevated debt levels.

Further, the used-car market remains highly sensitive to interest rates and consumer affordability challenges -- somewhat unpredictable macroeconomic factors.

Ultimately, while the company's slight improvement in retail unit sales volume is encouraging, the overall picture remains murky -- and the stock looks closer to fairly valued than clearly undervalued. CarMax's combination of soft top-line growth, a paused share repurchase program, and a leadership transition introduces a level of uncertainty that makes the stock worth avoiding unless it falls to a price at which it is trading as a clear bargain.

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 14, 2026, CarMax issued a press release reporting its financial results for the fourth quarter and fiscal year of 2026.  Despite its fourth-quarter results meeting or exceeding expectations for same-store sales and revenue, on a related earnings call, Company management indicated that it would, among other things, lower prices for used cars and increase its appetite for customers with lower credit scores to mitigate the impacts of an affordability crisis in the auto industry. 

On this news, CarMax’s stock price fell $7.42 per share, or 15.12%, to close at $41.66 per share on April 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 14, 2026, CarMax issued a press release reporting its financial results for the fourth quarter and fiscal year of 2026. Despite its fourth-quarter results meeting or exceeding expectations for same-store sales and revenue, on a related earnings call, Company management indicated that it would, among other things, lower prices for used cars and increase its appetite for customers with lower credit scores to mitigate the impacts of an affordability crisis in the auto industry. 

On this news, CarMax’s stock price fell $7.42 per share, or 15.12%, to close at $41.66 per share on April 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. ("CarMax" or the "Company") (NYSE: KMX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 14, 2026, CarMax issued a press release reporting its financial results for the fourth quarter and fiscal year of 2026. Despite its fourth-quarter results meeting or exceeding expectations for same-store sales and revenue, on a related earnings call, Company management indicated that it would, among other things, lower prices for used cars and increase its appetite for customers with lower credit scores to mitigate the impacts of an affordability crisis in the auto industry. 

On this news, CarMax's stock price fell $7.42 per share, or 15.12%, to close at $41.66 per share on April 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 14, 2026, CarMax issued a press release reporting its financial results for the fourth quarter and fiscal year of 2026.  Despite its fourth-quarter results meeting or exceeding expectations for same-store sales and revenue, on a related earnings call, Company management indicated that it would, among other things, lower prices for used cars and increase its appetite for customers with lower credit scores to mitigate the impacts of an affordability crisis in the auto industry. 

On this news, CarMax’s stock price fell $7.42 per share, or 15.12%, to close at $41.66 per share on April 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. ("CarMax" or the "Company") (NYSE: KMX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

          The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

          On April 14, 2026, CarMax issued a press release reporting its financial results for the fourth quarter and fiscal year of 2026. Despite its fourth-quarter results meeting or exceeding expectations for same-store sales and revenue, on a related earnings call, Company management indicated that it would, among other things, lower prices for used cars and increase its appetite for customers with lower credit scores to mitigate the impacts of an affordability crisis in the auto industry. 

          On this news, CarMax's stock price fell $7.42 per share, or 15.12%, to close at $41.66 per share on April 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. ("CarMax" or the "Company") (NYSE: KMX).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 14, 2026, CarMax issued a press release reporting its financial results for the fourth quarter and fiscal year of 2026.  Despite its fourth-quarter results meeting or exceeding expectations for same-store sales and revenue, on a related earnings call, Company management indicated that it would, among other things, lower prices for used cars and increase its appetite for customers with lower credit scores to mitigate the impacts of an affordability crisis in the auto industry. 

On this news, CarMax's stock price fell $7.42 per share, or 15.12%, to close at $41.66 per share on April 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

-

RICHMOND, Va.--(BUSINESS WIRE)--CarMax, Inc. (NYSE:KMX) will report its financial results for the first quarter ended May 31, 2026 before the market opens on June 17, 2026, and it will host a conference call with investors at 8:00 a.m. ET to discuss these results. Please note that the Company has changed the time of its earnings conference calls to 8:00 a.m. ET.

Participants on the call will include Keith Barr, President and CEO, Enrique Mayor-Mora, Executive Vice President, CFO and Jon Daniels, Executive Vice President, CarMax Auto Finance. The live conference call can be accessed by dialing (800) 225-9448 (or (203) 518-9708 for international access) and entering the conference ID 3171396. A live audio webcast also will be available at investors.carmax.com.

A replay of the webcast will be available on the company’s website at investors.carmax.com through September 28, 2026 or via telephone (for approximately one week) by dialing (800) 839-1247 (or (402) 220-0470 for international access).

June 23, 2026 – CarMax Annual Meeting of Shareholders

The CarMax 2026 annual meeting of shareholders will be held on Tuesday, June 23, 2026 beginning at 1:00 p.m. ET. The meeting will be held virtually and there will be no in-person meeting location. A live webcast of the meeting will be available at investors.carmax.com and a webcast replay will be available following the event.

About CarMax

CarMax, the nation’s largest retailer of used autos, revolutionized the automotive retail industry by driving integrity, honesty and transparency in every interaction. The company offers a truly personalized experience with the option for customers to do as much, or as little, online and in-store as they want. During the fiscal year ended February 28, 2026, CarMax sold approximately 780,000 used vehicles and 540,000 wholesale vehicles at its auctions. In addition, CarMax Auto Finance originated $8 billion in auto loans during fiscal 2026, adding to its nearly $16 billion portfolio. CarMax has more than 255 store locations, approximately 28,000 associates, and is proud to have been recognized for 22 consecutive years as one of the Fortune 100 Best Companies to Work For®. CarMax is committed to helping its communities thrive and reducing the environmental footprint of its operations. Learn more in the 2026 Responsibility Report. For more information, visit www.carmax.com.

More News From CarMax, Inc.

Back to Newsroom

The market expects CarMax (KMX - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended May 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on June 17. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis used car dealership chain is expected to post quarterly earnings of $0.94 per share in its upcoming report, which represents a year-over-year change of -31.9%.

Revenues are expected to be $7.54 billion, down 0.1% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.08% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CarMax?For CarMax, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.85%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that CarMax will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CarMax would post earnings of $0.22 per share when it actually produced earnings of $0.34, delivering a surprise of +54.55%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CarMax doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Hologic, Inc. (NASDAQ: HOLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,539 shares of the medical equipment provider's stock, valued at approximately $576,000. A number of other

WASHINGTON--(BUSINESS WIRE)---- $HOLX #gallup--1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates.

Key Takeaways Hologic's data reveals rising rates of women screened for blood pressure, cancer and diabetes.Hologic finds STI testing stagnant at 10%, with no improvement in five years.Hologic expands molecular diagnostics with Aptima tests for STIs and HPV. Hologic’s fifth edition of the Global Women’s Health Index highlights a persistent screening gap for key preventable conditions. Developed in partnership with Gallup, the Index tracks progress in women’s health and well-being worldwide, based on an annual survey of 145,000 people in 144 countries and territories.

In year five, 39% of women were tested for high blood pressure, 13% for cancer and 24% for diabetes — all up several points from the previous year and also at their five-year highs. However, sexually transmitted infection (STI) testing was the only area that showed no improvement, with just 10% of women reporting being tested for an STI in the past 12 months, unchanged since year one. This leaves nearly 2 billion women of reproductive age at risk of infertility, increased maternal and fetal mortality, and serious diseases.

Hologic’s Aptima family of molecular diagnostic assays covers common STIs such as chlamydia and gonorrhea, certain high-risk human papillomavirus (HPV) strains, Mycoplasma genitalium and Herpes Simplex viruses 1 and 2. The FDA-cleared BV and CV/TV assays for diagnosing vaginitis — a prevalent health issue affecting millions of women annually — now rank as the company’s second-largest assay worldwide. These tests have been a major growth driver for the past several quarters. Overall, Molecular Diagnostics business revenues fell 3.5% in the first quarter of fiscal 2026, partly due to lower sales of Aptima CT/NG and HPV assays and related collection devices.

In 2026, an estimated 13,490 new cases of invasive cervical cancer are likely to be diagnosed, with roughly 4,200 deaths — many of which are preventable with regular screening and appropriate follow-up on abnormal results.  In February, Hologic expanded its cervical health portfolio with FDA approval for Aptima HPV Assay for clinician-collected HPV primary screening.

HOLX’s Peer UpdatesQIAGEN (QGEN - Free Report) recently received FDA clearance for the use of all QIAstat-Dx Gastrointestinal Panels on the QIAstat-Dx Rise automated syndromic testing system. With this development, laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system. QIAGEN launched QIAstat-Dx Rise in the United States in September 2025 to address the rising demand for higher testing capacity and increased automation in molecular diagnostics laboratories.

GE HealthCare (GEHC - Free Report) has completed the acquisition of medical imaging software provider Intelerad. The latter’s technology and customer base will extend GE HealthCare’s reach into high-growth specialized clinics and ambulatory care environments, complementing the company’s strength in hospital-based imaging. Intelerad’s revenues in the first full year of ownership are expected to be roughly $270 million, of which approximately 90% is recurring.

The Zacks Rundown for HologicIn the past 12 months, Hologic shares have risen 23.1% against the industry’s 6.7% fall.

Image Source: Zacks Investment Research

In terms of valuation, Hologic is trading at a forward five-year price-to-earnings (P/E) of 16.11X, lower than its median and industry average. 

Image Source: Zacks Investment Research

Take a look at how estimates for Hologic’s earnings are shaping up.

Image Source: Zacks Investment Research

HOLX stock currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Hologic's buyout of up to $79 per share offers just 0.6% upside from recent levels.Align Technology hit $4B revenues in 2025, with aligner volumes rising 6.7% globally.DSO growth and digital tools adoption are boosting Align Technology's long-term expansion. Hologic  and Align Technology (ALGN - Free Report) are two well-established players in the medical technology (MedTech) market, each with distinct niche. Hologic develops diagnostics, surgical, and medical imaging technologies to advance women’s health. In the last five years, a series of tactical acquisitions helped expand the company’s existing businesses.

Align Technology designs and sells Invisalign clear aligners for the treatment of malocclusions, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (“CAD/CAM”) software for dental laboratories and practitioners. The company also invests in clinical support, product improvements, technological innovations, clinical education and advertising to supplement growth.

With the global MedTech market projected to reach $666.25 billion, per Statista, investors are closely tracking opportunities in this sector to enhance their portfolio. Here’s a closer look at how the two companies currently stack up.

The Case for HOLXHologic’s Diagnostics division is largely driven by sales of the Molecular Diagnostics assays. Performance wise, the unit’s revenues fell 3.5% in the first quarter of 2026, mainly due to lower sales of COVID-19 tests and legacy assays for sexually transmitted infections (STIs). The decline was partially offset by stronger sales of BV CV/TV and Panther Fusion assays.

Last year, Hologic’s new Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays secured the FDA’s 510(k) clearance and CE-IVDR approval in the European Union.  In addition, Biotheranostics is seeing strong adoption of Breast Cancer Index (BCI), a test that determines the benefit of extended endocrine therapy.

Within Breast Health, the acquisition of Endomagnetics in 2024 enhanced the Interventional business with cutting-edge products and R&D capabilities, contributing to the 1.8% revenue growth in the first quarter. Hologic is set to commercially launch the Envision Mammography Platform this year, offering patients a high-speed 3D mammogram with an industry-leading 2.5-second scan time.

The GYN Surgical division held momentum, with first-quarter sales up 8.7% year over year, driven by the Gynesonics acquisition and higher sales volume of MyoSure devices and Fluent Fluid Management products.

Hologic’s $18.3 billion take-private deal is edging toward completion, with 99.8% shareholder approval secured at the Feb. 5 special meeting. Under the terms, Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash, plus a non-tradable contingent value right (CVR) tied to certain global Breast Health revenue goals in fiscal 2026 and 2027. The aggregate purchase price of up to $79 per share represents a 46% premium to the May 23 closing price. With the stock closing yesterday’s session at $75.54, the cash offer implies a mere 0.6% upside.        

The Case for ALGNAlign Technology’s total revenues reached a record $4 billion in 2025. In the fourth quarter, clear aligner volumes increased 6.7% year over year, driven by strong performance in EMEA, Latin America and APAC, along with stability in North America, and supported by growth among adult, teen and pediatric patients, as well as across GP and orthodontic channels.

A major strategic growth channel for Align Technology is the Dental service and orthodontic service organizations, DSOs or OSOs, which are growing faster than the traditional practices globally. Their scale, operational discipline, and need for consistent, tech-enabled workflows are driving rapid adoption of the company’s Invisalign system, iTero scanners and fully digital workflows across large networks of general dentists and orthodontists.

Align Technology’s portfolio strategy, including products with lower upfront cost options, is expanding access for doctors while supporting margins. Products such as Invisalign First, the Invisalign palate expander and Mandibular Advancement with Occlusal Blocks (MAOB) continues to fuel year-over-year growth across all regions. As of December 2025, more than 296,000 active Invisalign-trained doctors have treated more than 22 million people worldwide, including over 6.5 million teens.

The company’s expanding suite of digital diagnostic tools, including Align Oral Health Suite and Align X-ray Insights, supports earlier diagnosis and more informed treatment planning. When combined with the restorative capabilities of exocad and the visualization strength of iTero, these tools connect straightening, function and restorative care with a unified digital platform.

As of 2025 end, the company’s cash and cash equivalents totaled $1.09 billion with zero debt on its balance sheet. 

EPS Projections for HOLX & ALGNThe Zacks Consensus Estimate for Hologic’s fiscal 2026 earnings indicates 5.4% year-over-year growth to $4.49. In the past 60 days, the estimate has moved downward. 

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Align Technology’s 2026 EPS indicate 6.7% year-over-year growth to $11.21. The estimate has been revised upward in the past 60 days.

Image Source: Zacks Investment Research

HOLX vs. ALGN: Price Performance & ValuationIn the past three months, Hologic shares have climbed 1.5%, whereas Align Technology surged 13.2%. 

Image Source: Zacks Investment Research

Hologic currently trades at a forward, two-year, price-to-sales (P/S) of 3.86X, slightly higher than its median. Align Technology’s 3.02X P/S sits below its median. 

Image Source: Zacks Investment Research

End NoteWhile Hologic carries strong underlying fundamentals, lower COVID testing and legacy STI test sales have weighed on its recent Diagnostics performance. With its buyout deal progressing, the small spread between the cash offer price and current levels suggests limited upside. Hence, it seems wise for current shareholders to consider exiting their position.

On the other hand, Align Technology is driving record Clear Aligner volume growth and continues to make strong progress with DSOs, its strategic growth channel. Analyst sentiment remains positive, reflected in the company’s rising earnings estimates. Given its attractive valuation, existing investors may want to retain their stock position for long-term gains. 

ALGN carries a Zacks Rank #3 (Hold), while HOLX has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Hologic has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this medical device maker have returned +0.1%, compared to the Zacks S&P 500 composite's -7.6% change. During this period, the Zacks Medical - Instruments industry, which Hologic falls in, has lost 9.9%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Hologic is expected to post earnings of $1.09 per share, indicating a change of +5.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $4.49 for the current fiscal year indicates a year-over-year change of +5.4%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $4.9 indicates a change of +9% from what Hologic is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Hologic.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Hologic, the consensus sales estimate of $1.05 billion for the current quarter points to a year-over-year change of +4%. The $4.26 billion and $4.48 billion estimates for the current and next fiscal years indicate changes of +4% and +5.2%, respectively.

Last Reported Results and Surprise HistoryHologic reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +2.5%. EPS of $1.04 for the same period compares with $1.03 a year ago.

Compared to the Zacks Consensus Estimate of $1.07 billion, the reported revenues represent a surprise of -2.14%. The EPS surprise was -4.59%.

Over the last four quarters, Hologic surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Hologic is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Hologic. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Blackstone/TPG Acquisition.

MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately.

“Hologic is an incredible company with a storied history of innovation and an unparalleled reputation as a leader in women’s health,” said Almeida. “I am thrilled to be joining at such a pivotal moment. With the backing of Blackstone and TPG, we are poised to take the organization to new heights, with a renewed sense of purpose and greater resources to invest in innovation and initiatives that will advance the mission of enabling healthier lives around the world.”

The transaction was announced on October 21, 2025, and was approved by Hologic stockholders on February 5, 2026. With the completion of the acquisition, Hologic stockholders will receive $76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to $3 per share in two payments of up to $1.50 each, for total consideration of up to $79 per share in cash. The non-tradable CVR would be paid, in whole or in part, following achievement of certain global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.

Ram Jagannath, Senior Managing Director and Global Head of Healthcare at Blackstone said, “Hologic has established itself as a global leader in advancing women’s health, with a proven track record of delivering life-changing medical technologies. We are thrilled to partner with Joe Almeida — an exceptional medical technology leader — alongside Hologic’s talented team and TPG to drive the company’s next phase of growth and innovation.”

“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide,” said Alex Albert, Partner at TPG and Co-Head of Healthcare for TPG Capital. “Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. Under Joe’s experienced and proven leadership, we are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.”

Almeida was most recently Chairman, President and Chief Executive Officer of Baxter International Inc., where he served from 2016 to early 2025. During his tenure, he led a strategic repositioning of the company, focusing on operational improvement, portfolio changes and medical product innovation.

Prior to Baxter, Almeida served as Chairman, President and CEO of Covidien plc until its acquisition by Medtronic in 2015. Before joining Covidien, he held senior leadership roles at Tyco Healthcare, and previously served in executive positions at Wilson Greatbatch Technologies, Acufex Microsurgical and Codman & Shurtleff, a division of Johnson & Johnson. A native of Brazil, Almeida holds a Bachelor of Science in mechanical engineering from Instituto Mauá de Tecnologia in São Paulo.

Almeida succeeds Stephen MacMillan, who recently retired from his role as Chairman, President and CEO after more than 12 years leading the organization.

Hologic’s common stock has ceased trading and will be delisted from the Nasdaq Stock Market.

About Hologic

Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com.

About Blackstone

Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s $1.3 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.

About TPG

TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with $303 billion of assets under management and investment and operational teams around the world. TPG invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, and market solutions, and our unique strategy is driven by collaboration, innovation, and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities.

Cautionary Statement Regarding Forward-Looking Statements

This news release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “likely,” “future,” “strategy,” “potential,” “seeks,” “goal” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of closing the merger. These forward-looking statements are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

These forward-looking statements are subject to a number of risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, including without limitation, risks related to disruption of management time from ongoing business operations due to the transaction; the risk of any litigation relating to the transaction; the risk that the transaction could have an adverse effect on the ability of Hologic to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive less-than-anticipated payments with respect to the CVRs. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the Hologic Annual Report on Form 10-K for the fiscal year ended September 27, 2025 filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by Hologic from time to time with the SEC. These filings, when available, are available on the investor relations section of the Hologic website at https://investors.hologic.com or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Source: Hologic, Inc.

More News From Hologic, Inc.

BOSTON--(BUSINESS WIRE)--OM1 helped power a 650,000-patient real-world evidence study supporting FDA approval of Hologic's Aptima HPV Assay for cervical cancer screening.

Concurrent Investment Advisors LLC lifted its stake in PulteGroup, Inc. (NYSE:PHM – Free Report) by 166.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,753 shares of the construction company’s stock after acquiring an additional 10,467 shares during the period. Concurrent Investment Advisors LLC’s holdings in PulteGroup were worth $1,964,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in PHM. Massachusetts Financial Services Co. MA bought a new stake in PulteGroup during the third quarter valued at $315,883,000. AGF Management Ltd. bought a new stake in PulteGroup during the third quarter valued at $174,347,000. American Century Companies Inc. boosted its stake in PulteGroup by 120.4% during the third quarter. American Century Companies Inc. now owns 1,703,049 shares of the construction company’s stock valued at $225,024,000 after buying an additional 930,287 shares during the period. Franklin Resources Inc. boosted its stake in PulteGroup by 5.0% during the third quarter. Franklin Resources Inc. now owns 12,900,271 shares of the construction company’s stock valued at $1,704,513,000 after buying an additional 609,640 shares during the period. Finally, First Trust Advisors LP boosted its stake in PulteGroup by 13.3% during the third quarter. First Trust Advisors LP now owns 3,623,917 shares of the construction company’s stock valued at $478,828,000 after buying an additional 424,011 shares during the period. 89.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In A number of research firms have weighed in on PHM. Seaport Research Partners restated a “sell” rating and set a $100.00 price target (down from $155.00) on shares of PulteGroup in a research report on Tuesday, April 7th. Zacks Research upgraded PulteGroup from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Truist Financial lowered their price target on PulteGroup from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Thursday, April 16th. Wells Fargo & Company raised their price target on PulteGroup from $132.00 to $140.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Weiss Ratings upgraded PulteGroup from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, January 12th. Eleven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, PulteGroup has an average rating of “Moderate Buy” and an average price target of $140.71.

Get Our Latest Analysis on PHM

Insider Activity at PulteGroup In other PulteGroup news, insider Ryan Marshall sold 111,250 shares of PulteGroup stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $133.86, for a total transaction of $14,891,925.00. Following the sale, the insider directly owned 659,392 shares of the company’s stock, valued at approximately $88,266,213.12. The trade was a 14.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Matthew William Koart sold 15,309 shares of PulteGroup stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $135.79, for a total value of $2,078,809.11. Following the sale, the chief operating officer directly owned 42,418 shares in the company, valued at approximately $5,759,940.22. The trade was a 26.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 149,952 shares of company stock worth $20,162,165 over the last 90 days. 0.75% of the stock is owned by insiders.

PulteGroup Stock Down 2.7% PHM opened at $124.87 on Wednesday. The company has a market cap of $23.79 billion, a P/E ratio of 12.08, a P/E/G ratio of 1.62 and a beta of 1.33. The business’s 50-day moving average price is $124.96 and its 200-day moving average price is $124.73. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 0.14. PulteGroup, Inc. has a 12 month low of $95.20 and a 12 month high of $144.49.

PulteGroup (NYSE:PHM – Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The construction company reported $1.79 EPS for the quarter, missing the consensus estimate of $1.80 by ($0.01). PulteGroup had a return on equity of 16.41% and a net margin of 12.14%.The company had revenue of $3.41 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter in the prior year, the firm posted $2.57 EPS. The firm’s quarterly revenue was down 12.4% on a year-over-year basis. On average, equities analysts expect that PulteGroup, Inc. will post 10.06 EPS for the current year.

PulteGroup Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Thursday, April 2nd. Investors of record on Tuesday, March 17th were issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Tuesday, March 17th. PulteGroup’s payout ratio is currently 10.06%.

PulteGroup declared that its board has initiated a stock repurchase plan on Thursday, April 23rd that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the construction company to repurchase up to 6.1% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

PulteGroup Profile (Free Report)

PulteGroup, Inc (NYSE: PHM) is a U.S.-based residential homebuilder that designs, constructs and sells single-family homes and develops master-planned communities. The company operates multiple national and regional brands that target different buyer segments, including first-time buyers, move-up buyers and active-adult customers. Its operations encompass land acquisition and development, home design and construction, community amenities and ongoing customer service and warranty programs.

PulteGroup markets homes under several well-known brands, such as Pulte Homes, Centex and Del Webb, among others, offering a range of product types from entry-level detached homes to larger, higher-end residences and age-restricted active-adult communities.

Featured Articles Five stocks we like better than PulteGroup

Receive News & Ratings for PulteGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PulteGroup and related companies with MarketBeat.com's FREE daily email newsletter.

Span, a California-based startup, has developed small, fractional data centers, or “nodes,” called XFRA units. The idea is to take advantage of unused electrical capacity on local grids, which the Span smart panels can pinpoint.

PulteGroup (PHM - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this homebuilder have returned -4.4%, compared to the Zacks S&P 500 composite's +11% change. During this period, the Zacks Building Products - Home Builders industry, which PulteGroup falls in, has gained 2.4%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, PulteGroup is expected to post earnings of $2.43 per share, indicating a change of -19.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -8.9% over the last 30 days.

The consensus earnings estimate of $10 for the current fiscal year indicates a year-over-year change of -12.6%. This estimate has changed -1.5% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $11.14 indicates a change of +11.4% from what PulteGroup is expected to report a year ago. Over the past month, the estimate has changed -2.6%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for PulteGroup.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of PulteGroup, the consensus sales estimate of $4.07 billion for the current quarter points to a year-over-year change of -7.5%. The $16.44 billion and $16.94 billion estimates for the current and next fiscal years indicate changes of -5% and +3.1%, respectively.

Last Reported Results and Surprise HistoryPulteGroup reported revenues of $3.41 billion in the last reported quarter, representing a year-over-year change of -12.4%. EPS of $1.79 for the same period compares with $2.57 a year ago.

Compared to the Zacks Consensus Estimate of $3.38 billion, the reported revenues represent a surprise of +0.7%. The EPS surprise was -0.56%.

Over the last four quarters, PulteGroup surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

PulteGroup is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about PulteGroup. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

In April, mortgage applications soared 21% year over year, per the Mortgage Bankers Association. Did it happen due to plunging interest rates? Nope -- the average interest rate for most 30-year fixed-rate mortgages actually moved up a notch, as of May 7, from 6.30% the week before to 6.37%, per Freddie Mac. (Those rates are down a mite from a year ago, when the average was 6.76%.)

There are multiple explanations for the rise in mortgage applications -- and multiple beneficiaries.

Image source: Getty Images.

Here are some explanations:

Pent-up demand: While many would-be homebuyers have been waiting for significantly lower rates before they buy, plenty don't want to wait any longer, or can't. Lower rates: Interest rates are down a little now. Less expectation of lower rates: Many people may no longer be expecting interest rates to fall sharply anytime soon -- because of inflation. When inflation rises, the Federal Reserve will act to cool the economy by hiking interest rates. Homebuilders positioned to profit When many people are looking to buy homes, that's good news for homebuilders. Here are a few to consider for your long-term portfolio:

1. Lennar Lennar (LEN 4.31%), with a recent market value near $21 billion, is a major American homebuilder, recently sporting a dividend yield of 2.2% -- and a total shareholder yield (including the effect of share buybacks) of 8.5%.

Today's Change

(

-4.31

%) $

-4.09

Current Price

$

90.86

It has a lot going for it, such as the fact that the U.S. housing market needs a lot more homes -- especially as millennials look to buy. In its first quarter, Lennar posted a decrease in revenue, but also noted a backlog of 15,588 homes, worth about $6 billion, and a 1% increase in new orders, to 18,515. Interestingly, Lennar and some other homebuilders are proposing building starter "Trump Homes" -- which could potentially spur sales.

Clearly, Lennar isn't firing on all cylinders in this environment, but that may be why its stock seems reasonably valued, with a recent price-to-sales ratio of 0.65, below the five-year average of 1.0. The recent price-to-earnings (P/E) ratio of 12.2 is a bit above the five-year average of 8.4.

2. DR Horton DR Horton (DHI 0.47%) is an even larger homebuilder, with a recent market value of nearly $40 billion. Its recent dividend yield of 1.2% is smaller than Lennar's, but its total yield (including share buybacks) is higher, at a recent 9.9%.

Today's Change

(

-0.47

%) $

-0.72

Current Price

$

153.71

It has built more than a million homes in America, and is poised to build more. Its second quarter also featured falling revenue (by 2% year over year) -- and a rising backlog of orders, worth about $6.4 billion.

A word of caution Despite some optimism for homebuilders, it's not the best of times overall. Buying now might serve you well -- especially if you collect a dividend while you wait -- but homebuilders may continue to face headwinds for longer. The war with Iran, for example, could disrupt our economy, as some tariffs already have, and inflation is pinching many consumers' pockets. If the economy slows, so will enthusiasm for homebuying -- though, of course, things do change over time, and people will still need and want to buy homes over the long run.

On May 20, 2026, PulteGroup Inc (PHM) shares rose 4.7% to a current price of $116.26. This increase comes amidst a 52-week trading range of $95.20 to $144.50, r